Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2).

Additionally, consistent with results in PRIME, but in contrast to PRIME2, the pooled analysis showed nominally significant improvements in sleep quality from week 4 to week 24. 12 Analyses by baseline demographic subgroups showed a consistent trend of dupilumab benefit compared with placebo in achieving ≥4-point reduction in WI-NRS, IGA PN-S 0 or 1, or both, at week 24, with comparable effect size in all demographic subgroups that included sufficient patients for meaningful testing.

also in 7,732 other papers